16 September 2026 editorial review · Item
Sorafenib for recent-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added a narrow repurposing entry. Checked trial status, target 10, adult eligibility, insulin continuation and dates; current Bayer-hosted US label supports known drug warnings and cancer indications.
- Primary sources checked: NCT06227221 — study record (registry); Nexavar (sorafenib) US prescribing information, revised August 2023 (regulatory).
- Limits: Registry still not yet recruiting despite passed estimated start. No T1D benefit or safety outcomes. Selective immune mechanism is not asserted; category is editorial grouping.